Source BioScience PLC Additional Listing on Exercise of Share Options (7330J)
September 13 2016 - 10:23AM
UK Regulatory
TIDMSBS
RNS Number : 7330J
Source BioScience PLC
13 September 2016
13 September 2016
Source BioScience plc
(or "the Company")
Additional Listing on Exercise of Share Options
Source BioScience plc (LSE: SBS) announces that it has issued
10,775,135 new Ordinary Shares of 2 pence each in the Company ("New
Ordinary Shares"), following the exercise of share options under
the Company's 1999 Unapproved Share Option Scheme.
Application has been made for the new Ordinary Shares to be
admitted to the Official List of the UK Listing Authority and to
trading on the Main Market of the London Stock Exchange. Admission
of the new Ordinary Shares is expected on 14 September 2016.
Following the issue and allotment, the Company's issued share
capital will comprise 360,126,216 Ordinary Shares of 2 pence each.
This figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or change to their interest in, the
Company under the FCA's Disclosure and Transparency Rules. The new
Ordinary Shares will rank pari passu with existing Ordinary
Shares.
Pursuant to Rule 2.10 of the Code, Source BioScience confirms
that there are 360,126,216 ordinary shares of 2 pence each in issue
with International Securities Identification Number
GB0009739649.
Enquiries
Source BioScience plc
Dr Nick Ash, Company Secretary
Tel: +44 (0) 115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
About Source BioScience:
Source BioScience plc (LSE: SBS) is a trusted provider of state
of the art Laboratory Services and Products to the healthcare and
clinical, life and applied sciences and biopharma industries. It is
an international business operating ten state of the art facilities
in five countries and with customers in over 90 countries
worldwide. The Group offers a complementary portfolio of Laboratory
Services and Products that share common technologies, laboratory
processes, infrastructure and expertise. These include Diagnostics,
DNA Sequencing and Genomics, Analytical and Regulated Services,
Clinical Products, Life Science Research Reagents and Controlled
Environment for a comprehensive range of applications. These
Laboratory Services and Products are provided to a large and
diverse customer base including the top 50 pharmaceutical
companies, leading universities and research institutes worldwide,
the UK NHS and other healthcare providers. The Group is listed on
the Premium Main Market of the London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
ALSLLFFSAFIVLIR
(END) Dow Jones Newswires
September 13, 2016 10:23 ET (14:23 GMT)
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Oct 2024 to Nov 2024
Source Bioscience (LSE:SBS)
Historical Stock Chart
From Nov 2023 to Nov 2024
